'Mmp 9' diaporamas de présentation

Nov 23 at 8am

Nov 23 at 8am. Sala Dios Candangos. Non-Eosinophilic Asthma: Mechanisms and Treatment. Prof Peter G Gibson NHMRC Centre for Respiratory and Sleep Medicine Newcastle, Australia. FEV 1 %: 70% pred BDR%: 15% PC 20 : 0.13 SABA : 6.5. 88% 13% 0.45 mg/ml 3.8 puffs/day.

901 views • 73 slides

Dennis Yue Director of Diabetes, Royal Prince Alfred Hospital

The Multi-disciplinary Diabetes Centre : A Model of Care for the Future (or the Past) ?. Dennis Yue Director of Diabetes, Royal Prince Alfred Hospital Kellion Professor of Endocrinology, University of Sydney. Conference in China. The Burden and Complexity of Diabetes.

703 views • 55 slides

RNA ???? CD147 ???????? SGC7901 ??????????????

RNA ???? CD147 ???????? SGC7901 ??????????????. ??? MD, PhD ??????????????. 2010.5.18. ????. ???? ???? ??????? ????. ?? ????. ????. ??????????????????????? ??????????????????????????????? ????? ?. MMP ??.

661 views • 48 slides

Oxygen therapy reduces secondary hemorrhage after thrombolysis in thromboembolic cerebral ischemia

628 views • 44 slides

Better Regimens & Predictive Markers For Advanced Esophagogastric Cancer?

294 views • 21 slides

E 00-16

Inserm. New cells for new purposes: use of gingival fibroblast for arterial repair Antoine LAFONT, MD, PHD, FESC, Hopital Europeen Georges Pompidou INSERM U849 PARIS-DESCARTES University FRANCE. E 00-16. AAA: which target ?. Loss of smooth muscle cells Destruction of elastin network

429 views • 19 slides

Garlic & Health: Health part - general aim

Garlic & Health: Health part - general aim. Main Goal: - Interactive improvement of garlic quality Elucidation of mechanism Analysis of active of action compounds Improved drug formulation High quality garlic Improvement of garlic Optimal use of garlic

414 views • 17 slides

Biomedical Engineering and Biomedical Informatics Program

Biomedical Engineering and Biomedical Informatics Program. Barbara Beckerman Modeling and Simulation Group Computational Sciences and Engineering Division. Biomedical engineering and biomedical informatics research at ORNL. Biokinetic and biotransport modeling

401 views • 12 slides

Purpose

The expression of inflammatory cytokines in chemical- or microkeratome-assisted corneal epithelial flaps in rabbits. Taehyung Lim, MD 1,2,4 , Hyuk- Jin Choi MD 1,2 , Hyun Joo Lee 1,2 , Mee Kum Kim, MD 1,2 , Won Ryang Wee, MD 1,2 , Jin Hak Lee, 2,3

199 views • 12 slides

Introduction

Sensitivity and Specificity of a Point-of-Care Matrix Metalloproteinase 9 Immunoassay for Diagnosing Inflammation Related to Dry Eye.

171 views • 9 slides

100

120. 140. 120. 100. 100. 80. Relative FITC Signal (%). Relative FITC Signal (%). 80. 60. 60. 40. 40. 20. 20. 0. 0. 0. 20. 40. 60. 80. 100. 120. 0. 100. 200. 300. 400. Time (min). TUDCA ( m M). A. B. Supplemental Fig. 1. Kim et al. TUDCA. TUDCA. (min). (min). 0.

204 views • 5 slides

1756-9966-31-90-S1

Supplementary Figure 1 Immunofluorescence staining for ColIV in normal group, dysplastic oral mucosa group and OTSCC group.

159 views • 2 slides

?????????? ? ??? ? ??????? -9 ????????????????

?????????? ? ??? ? ??????? -9 ????????????????.

115 views • 2 slides

SACCHACHITIN P10 ????????????????

SACCHACHITIN P10 ????????????????.

136 views • 2 slides

1756 6606 6 14 S1

90 views • 1 slides

Introduction

Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)

118 views • 1 slides

Supplemental Figure 1

Serum concentration of cTnT. Activity of MMP-2/9. Before CPB. AfterCPB. Supplemental Figure 1.

65 views • 1 slides

Figure S4

A1. A2. P-Akt Ser 473. MMP-9. P-p70S6K Thr389. b -actin. b -actin. 100. 100. 100. 100. 100. 100. 250. 250. 250. 250. 250. 250. 500. 500. 500. 500. 500. 500. DMSO. DMSO. DMSO. DMSO. DMSO. DMSO. GDC-0941 nM. GDC-0941 nM. GDC-0941 nM. GDC-0941 nM. GDC-0941 nM.

163 views • 1 slides

Supplemental Figure 1

Serum concentration of cTnT. Activity of MMP-2/9. Before CPB. AfterCPB. Supplemental Figure 1.

74 views • 1 slides

1756-6606-6-14-s1

128 views • 1 slides